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tion, where MoH achieves equity principles by enhancing access to medicine among 
the poor, while pharmaceutical companies launch their products in the Egyptian 
market, with an acceptable return to their investments.
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Objectives: Japan is a low generic adoption market, and increased penetration has 
become a critical target to generate savings to fund innovative drugs and control 
healthcare expenditure. The objective of this research was to provide an overview 
of policies implemented in Japan to boost generics uptake and to assess impact of 
these measures. MethOds: Generics policies and uptake were identified through 
literature review from: Japanese authority website, Japan Generics Association 
website, Medline®, ICHUSHI® database and grey literature. Results: Generics 
policies have been implemented in Japan since 2002. In 2002, the National Health 
Insurance (NHI) medical fee schedule introduced financial incentives to prescribe 
generic drugs for providers (pharmacies and hospitals). Since then, various financial 
incentives to providers have been introduced by the biannual revision of NHI medi-
cal fee schedule. Diagnostic Procedure Classification system (bundled payment) 
encouraging generic drug use was introduced in acute care hospitals in 2003 and 
expanded to 21% of general hospitals (55% of hospital beds) in 2014. In 2007, the 
government put in place an action plan to encourage generic drug use. This was 
complemented in 2013 by a roadmap aiming at increased generic penetration to 
exceed 60% by 2018. More aggressive financial incentives were introduced in April 
2014 setting up generic volume threshold for pharmacies. The generic market share 
was continuously increased from 32.5% (2005), 39.9% (2011), to 47.9% (2013), and 
rapidly increased from 51.2% (March 2014) to 57.1% (November 2014). The recent 
policy accelerating the generic market share targeting at least 70% by 2017 is under 
discussion at the economic advisory council and raise concern about excessive 
speed. cOnclusiOns: The recent health policy measures to increase generics 
uptake confirm this priority for policy decision makers in Japan. Following recent 
aggressive policies the Japanese generic market will soon match other developed 
countries.
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Objectives: Regarding the discussion on AMNOG in Germany that for certain 
diseases it might be more difficult to prove an additional benefit (AB) than for 
other ones, a respective analysis of benefit assessments was conducted consider-
ing the following disease categories: Chronic conditions, cancer, and infectious 
diseases. MethOds: In total, 91 benefit assessments finalized until 31 December 
2014 (except for drugs integrated into an existing reference price group) and entail-
ing 182 patient groups (PG) were analyzed. Results: A total of 41 benefit assess-
ments regarding chronic conditions entailing 89 PG (of which 52 were part of 
antidiabetic drug assessments) were conducted. An AB vs. the appropriate com-
parator could not be proven for 83% of PG. For antidiabetic drugs, this number even 
amounted to 90% (47 of 52 PG). A considerable AB was granted for only 2% of PG 
(Ticagrelor for NSTEMI patients and Belimumab for systemic lupus erythematosus 
with high disease activity). As opposed to chronic conditions, the proportions 
of PG without any AB were only 46% and 39% in cancer and infectious diseases, 
respectively. A considerable AB was granted for 28% und 18% of PG, respectively. In 
terms of assessments, no AB was granted for any PG in case of 30 (73%) out of 41 
benefit assessments regarding drugs for chronic conditions (including 11 out of 15 
assessments for antidiabetic drugs). As opposed to this, there was no AB acknowl-
edged in only 3 (27%) out of 11 assessments on drugs against infectious diseases 
and in only 5 (22%) out of 23 assessments on anticancer drugs. cOnclusiOns: 
There seems to be a correlation between disease category and the chance of AB 
recognition. Reasons for this could be the choice of an appropriate comparator 
as well as issues regarding patient-relevant endpoints. These results could be 
relevant discussing the further development of AMNOG.
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Objectives: the aim of this study was to identify the cohort of patients starting 
treatment with biologics in the years 2012-2013 and estimate the number of patients 
that switch therapy within the first 12 months. MethOds: Patients were enrolled 
based on data extrapolated from the File F and H- OSP File (Administrative data-
base) of the Lazio region (central region in Italy). The treatment-naïve patients has 
been defined as individuals who did not have a prescription in the two years before 
the index prescription. Patients that switch biologic therapy have been defined 
as therapeutic prescription different than Anatomical Therapeutic Chemical clas-
sification (ATC) of enrollment within one year of the index date. Biologic drug, 
hospitalization and concomitant drug cost have been included in the analysis. The 
information sources were linked with a deterministic record linkage and the patho-
logical condition was inferred from the treatment plan prescription of the Lazio 
Region. Results: From a total number of 33,027 patients treated with biologic 
drug between 2010-2014 in the Lazio region, it were estimated 3,002 treatment-
naïve patients (43% male). The most frequent prescription was related to Etanercept 
(974 patients, 32%), adalimumab (898 patients, 30%) and infliximab (524 patients, 
Objectives: The National Committee for Technology Incorporation (CONITEC) aims 
to support Ministry of Health in decisions on incorporation, exclusion or modi-
fication of technologies in the Brazilian Public Health System (SUS). For this, it 
produces reports with recommendations with different characteristics. To analyze 
the CONITEC reports on incorporation, exclusion or modification of health technolo-
gies in the SUS. MethOds: Descriptive study, based on the reports available at the 
CONITEC website, from July 2012 to April 2015. Reports were classified according to: 
type of technology, type of applicant, type of report, presence of Health Economic 
Evaluation (HEE), and the type of HEE. Results: One hundred and thirty two reports 
were analyzed. The type of technologies most frequently evaluated were: drugs 
(65.2%), procedures (19.7%) and materials (9.1%). The two major applicants were: 
Public Health System (51.5%) and pharmaceutical industry (37.1%). The majority of 
reports were classified as: Description of Technology (40%), Mini Health Technology 
Assessment (33%), Rapid Review (23%) and only 4% of the reports were Full Health 
Technology Assessment. One hundred and one reports studies included some eco-
nomic data, 53.5% (n = 54) were classified as partial HEE and 46.5% (n = 47) were 
full HEE. Among partial economic evaluation, initial estimates of budget impact 
analysis was the most frequent (n = 51; 94.4%) and among the full economic evalu-
ations, cost-effectiveness analysis (n = 20; 42.6%). Out of 47 full economic evalua-
tions, 33 (70.2%) presented the incremental cost-effectiveness ratios (ICERs). Of all 
the analyzed reports (n = 132), only 25% (n = 33) performed a complete HEE with 
ICER. cOnclusiOns: The type of technologies most frequently evaluated were 
drugs, and the major applicant was the Public Health System. The majority of the 
recommendations were based on Technology Description reports, and the most 
common HEE was initial estimates of budget impact analysis.
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Objectives: CONITEC has recommended for incorporation part of the technolo-
gies analyzed. Among the requested documents, applicants must provide a Health 
Economic Evaluation (HEE) under the SUS perspective, including an incremental 
cost-effectiveness ratio (ICER). However in the legal documents there is no explicit 
recommendation on the use of ICER and cost-effectiveness threshold (CET) as a 
criteria for technology recommendation. To analyze the CONITEC reports that 
recommended the incorporation of the technologies in the SUS from July 2012 to 
April 2015, and compare the values of the ICERs with CETs suggested in the litera-
ture. MethOds: Descriptive study, based on the reports available at the CONITEC 
website from July 2012 to April 2015. Reports were classified according to: type of 
technology, type of applicant, type of report, presence of HEE, and the type of HEE. 
ICER was compared with the CET recommended by WHO and Center of Health 
Economics (CHE)-University of York. Results: Seventy-two reports recommended 
the incorporation of the technology in the SUS. The most common technologies 
recommended were drugs (51.4%), procedures (30.6%) and materials (8.3%). The 
major applicant was the Public Health System (70.8%), followed by the pharmaceuti-
cal industry (8.3%). Most reports were classified as Technology Description (65.3%), 
followed by Rapid Review (19.4%), Mini Health Technology Assessment (8.3%), and 
only 6.9% the reports were Full HTA. Fifty-five reports conducted HEE, 80% (n = 
44) were partial and 20% (n = 11) were full. Of the Seventy-two technologies rec-
ommended for incorporation, only 8(11.1%) presented a full HEE with ICER. Seven 
technologies presented ICER below the CET proposed by WHO and only one below 
the CET proposed by CHE. cOnclusiOns: Most of the technologies recommended 
for incorporation were demanded by the Public Health System and were based on 
Technology Descriptions and Rapid Reviews. Use of a CET was not an essential 
criterion for recommending technology incorporation.
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intROductiOn: Egypt healthcare system shows high Out-Of-Pocket (OOP) expendi-
ture on health (72% of THE), with 40% of total OOP dedicated to pharmaceuticals. 
In an attempt to maintain patient access to affordable medicines, the Egyptian 
Ministry of Health (MoH) implements a strict pricing policy for pharmaceuticals. 
However, the current pricing system has some drawbacks and challenges. These 
challenges often cause delays in launch of some innovative medicines, shortage 
in some important medicines and dissatisfaction of the pharmaceutical industry 
about the low prices that put a great pressure on their operational sustainabil-
ity. Consequently the MoH decided to introduce some reform actions to address 
these problems, aiming to achieve fair pricing policy, using the differential pricing 
concept. Objectives: To explore different Methods of differential pricing within 
a country, to evaluate their applicability for Egypt by taking into account the inter-
national price referencing framework, and to provide recommendations for fair 
pricing of pharmaceuticals in Egypt. MethOds: A focus group of decision makers 
and industry experts was established to discuss the possible pricing options within 
the Egyptian healthcare system context and develop core assumptions before pre-
paring a draft report. The recommendations were developed by using the Quasi-
Delphi method. Results: Innovative pricing models, like differential pricing with 
confidential agreements, are expected to 1) shift the financial burden of pharma-
ceuticals’ price to the more affluent consumers and distribute the cost of innovation 
across the patients according to their socio-economic status, and 2) reduce negative 
externalities related to the international reference pricing system. cOnclusiOns: 
Differential pricing with confidential agreements would achieve a win-win situa-
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elderly are limited in literature. This study, therefore, aimed to evaluate the pre-
scription pattern specifically among Indian elderly patients using WHO prescrib-
ing indicators.
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Objectives: The aim of this study is to determine the main causes of the dynamics 
of outpatient drug expenditures in Austria on an aggregate view (ATC level 1) over 
the last 10 years and to identify the key factors for the current developments at a 
more detailed, therapeutic level. MethOds: The data comprise the filled prescrip-
tions at the expense of all statutory health insurance funds in Austria, covering 
more than 97% of the national population. Observation period is from 2005 to 2014, 
with a preview of 2015. Year-on-year changes are calculated at different ATC levels. 
Costs are in euros excluding VAT. Results: Pharmaceutical expenditures increased 
significantly from 2005 until 2008, while from 2009 to 2013 there were only moderate 
increases. In 2014, expenditures started to rise considerably again, the ATC groups J 
(antiinfectives), L (antineoplastics and immunomodulators), and B (blood and blood 
forming organs) practically being the sole causes. One steady development over 
the last 10 years is the constant cost increase in the group L. Group N (nervous 
system) was the second cost driver until 2011, but faded afterwards. Beginning 
with 2012, group B is one of the major cost drivers. There are recently no significant 
cost declines through losses of exclusivity, except for the year 2013. Looking more 
into detail, one can observe that the current rise is strongly dominated by the new 
hepatitis c drugs (part of group J), followed by direct oral anticoagulants (DOACs, 
part of group B). cOnclusiOns: The new hepatitis c drugs are the main cause for 
the current increases in public outpatient pharmaceutical expenditures in Austria. 
As there are no remarkable compensating savings via generic entries, the cost rise 
poses a severe challenge for the public health insurance system, especially amid 
continuing weak economic growth and therefore stressed health budgets.
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Objectives: To assess drug use pattern in outpatient departments (OPDs) 
of two tertiary care hospitals (Bahawal Victoria Hospital and Civil Hospital) of 
Bahawalpur, Pakistan. MethOds: This was a descriptive, non-experimental and 
cross-sectional study. For the prescribing indicators, 2,400 prescriptions (10 OPDs 
per hospital, 120 prescriptions per OPD) were systematically sampled out of the 
total 1,560, 000 prescriptions written during April 2014 to March 2015. A total of 600 
randomly selected patients (300 patients per hospital, 30 per OPD) and all pharma-
cists available in both hospitals were interviewed to investigate the patient-care 
and facility-specific indicators. We used published ideal standards for each of the 
WHO/INRUD indicators. Results: Among the prescribing indicators, the average 
number of drugs per encounter was 2.8 (SD = 1.3) (optimal value = 1.6–1.8), the 
drugs prescribed by generic name were 56.6% (optimal value = 100%), the encoun-
ters with an antibiotic prescribed were 51.5% (optimal value = 20.0–26.8%), the 
encounters with an injection prescribed were 0.0% (optimal value = 13.4–24.1%) 
and the drugs prescribed from Essential Drugs List (EDL) were 98.8% (optimal value 
= 100%). Among the patient-care indicators, the average consultation time was 
1.2 minutes (SD = 0.8) (optimal value ≥ 10 minutes), the average dispensing time 
was 8.7 seconds (SD = 4.9) (optimal value ≥ 90 seconds), the percentage of drugs 
actually dispensed was 97.3% (optimal value = 100%), the percentage of drugs 
adequately labeled was 97.3% (optimal value = 100%) and the patients’ knowledge 
of correct dosage was 61.6% (optimal value = 100%). Among the facility-specific 
indicators, both health care facilities had a copy of EDL and key drugs available 
in the stock were 72.4% (optimal value = 100%). cOnclusiOns: Irrational use of 
drugs was observed in both health care facilities. Continuous education of the 
physicians, increased physician-to-patient and pharmacist-to-patient ratio are 
some options to promote rational drug use.
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Objectives: Systematic literature reviews (SLRs) play an important role in 
evidence-based medicine and are increasingly favored over traditional narra-
tive reviews as a method to objectively summarize vast amounts of outcomes 
data. Our objective was to evaluate a cross-section of published SLRs in oncol-
ogy and determine the top journals, main purposes, meta-analysis frequency, 
and sponsorship. MethOds: Searches were conducted in Embase and MEDLINE 
for the year 2014 and further restricted to cancer topics. Case reports, editori-
als, conference abstracts, and letters were excluded. Abstracts were manually 
reviewed to identify SLRs, published in journals, and reporting oncology drug 
therapy. Results: A total of 1,510 unique citations were identified; 727 were 
determined to be SLRs in oncology. 9 SLRs included case reports describing rare 
cancers or adverse drug reactions. Drug therapy was noted in 391 publications 
(53.8%); 210 included meta-analysis. Journals publishing the largest number of 
SLRs were PLoS ONE (n= 30), Tumor Biology (n= 17), Cancer Treatment Reviews 
(n= 15), World Journal of Gastroenterology (n= 10) and Journal of Clinical Oncology 
(n= 9). Impact factors for these journals ranged from 2.369 to 17.879. Most fre-
quent purposes were treatment comparisons (27.9%), efficacy assessments (15.6%), 
17%). Considering the disease treatment distribution, 857 patients were treated for 
rheumatoid arthritis (28,55%), 811 for psoriatic arthritis (27,02%), 421 for psoria-
sis (14,02%) and remaining patients for other diseases (i.e. ankylosing spondylitis, 
ulcerative colitis) . 86 patients (25.8%) switch biologic therapy within the first 120 
days, 97 patients (29.22%) between 120 and 210 days, 82 patients (24.70%) between 
210 and 300 days, 67 patients (20, 18%) between 300 and 365 days. cOnclusiOns: 
The present study is able to provide a map of the current strategy of treatment 
with biologics in the region Lazio considering medical conditions and prescribed 
treatments.
PHP55
caPturinG accurate cOncOmittant medicatiOns infOrmatiOn in 
GlOBal trials
O’Donohoe P1, Lambe J2, Acquadro C3
1CRF Health, London, UK, 2Mapi, Lyon, France, 3Mapi Research Trust, Lyon, France
Objectives: To understand the full impact of a novel treatment, particularly in 
more subjective symptoms such as pain, capturing information on any additional 
medication a patient may have taken alongside the study drug is vital. Two major 
challenges to the accurate recording of this data in global clinical trials have been 1) 
producing “localisations” of concomitant medications that are applicable and com-
parable in all countries involved in the study; and 2) moving away from a reliance on 
retrospective, site-based capture from patients. The aim of this study was to develop 
and document an easy to use electronic diary solution combined with an appropri-
ately localised medication list. MethOds: An electronic medication diary which 
allowed for the recording of medication name, route of administration and dosage 
was developed for a handheld platform, with iterative testing and refinement in 
users. The solution included a pre-populated, tailored list of the patient’s most com-
mon drugs (n = 38), which could be localised on a country-by-country basis (n = 21) 
following a process for ensuring the appropriateness of the drug name in the local 
market. Results: The iterative approach to design and development ensured the 
development of an electronic solution which was user-friendly and intuitive. Over 
3 rounds of testing a number of updates were made based on feedback from user 
relating to the flow of the diary and the training module. Best practice for developing 
appropriate localised list of concomitant medication involved asking two local 
experts for feedback using in-country medical databases. cOnclusiOns: Accurate 
tracking of concomitant medication usage is an important aspect of assessing the 
effectiveness of a new treatment. A user-focused electronic diary solution over-
comes the limitations of traditional, retrospective approaches to capturing this 
information. Localisation of the concomitant drug list ensures accurate and com-
parable data captured across all studies in a trial.
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Objectives: This study aimed to evaluate the Prevalence and Perception Use of 
Non-Prescription medicines (NPM) among medical undergraduate students (i.e. 
from pharmacy, MBBS and nursing students) in Quetta, Pakistan. MethOds: A 
cross-sectional study was conducted by using self-administered questionnaire, 
which consists of 15 questions. Medical students i.e. pharmacy, MBBS and nursing 
students were included in the study from different institutes providing the medi-
cal education. he descriptive statistics (frequencies and percentage) was used to 
present the data . All analyses were performed using SPSS 20.0. Results: A total 
of 300 questionnaires were distributed and 260 were returned (Response rate of 
86.7%). Among 260 respondents females were 164 (63.1%). Majority of participants 
246 (94.6%) knew about Non-Prescription medicines (NPM), 240 (92.3%) were used 
NPM drugs and 228 (87.7%) purchases NPM easily form the pharmacies. one hundred 
and forty (53.8%) respondents know about contraindication of NPM drugs while 205 
(78.8%) recommended the use of NPM to friend and relatives. The major use of NPM 
is to relief ache, pain and other condition such as cough, cold, fever, diarrhea, dys-
menorrhea constipation, vomiting and flu etc. cOnclusiOns: This study showed 
that majority of the Medical students were aware of different non-prescription 
medicines and their use and high prevalence is present among medical student to 
use these NPM for minor illness.
PHP57
druG utilizatiOn study On indian elderly amBulatOry Patients 
usinG wHO PrescriBinG indicatOrs
Kashyap M1, D Cruz S2, Sachdev A2, Tiwari P3
1AIMST University, Semeling, Malaysia, 2Government Medical College & Hospital, Chandigarh, 
Chandigarh, Malaysia, 3National Institute of Pharmaceutical Education and Research, S.A.S. 
Nagar, Punjab, INDIA, Mohali, India
Objectives: Studies on the characterization of prescription among Indian elderly 
are limited in literature. This study, therefore, aimed to evaluate the prescription 
pattern specifically among Indian elderly patients using WHO prescribing indi-
cators. MethOds: Prescriptions of 4005 outpatients, age 60 yrs or above, were 
evaluated prospectively using WHO prescribing indicators. Results: The aver-
age age (±SEM) of patients was 68.28±0.11 yrs. On an average, each patient had 
2.01±0.01 diagnoses & was prescribed 6.45±0.04 drugs. The most common disorder 
was ‘Diseases of circulatory system”. The patients were prescribed an average of 
6.45±0.04 medications. Over half of the patients (57.9%) received more than five 
medications concurrently. The percentage of drugs prescribed by generic name 
was only 0.8%. Antibiotic usage was 13% while 7.3% of patients were prescribed 
injections. The percentage of drugs prescribed from National List of Essential 
Medicines 2003 was 66% of the drugs prescribed. cOnclusiOns: The minimal 
prescription of antimicrobials and injections coupled with higher prescriptions 
from essential drug list is a very positive reflection of good prescribing among 
elderly outpatients. Studies on the characterization of prescription among Indian 
